<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/category/news/science-news/cancer-science-news/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 28 Oct 2026 00:16:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Cancer &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Immunotherapy plus chemotherapy shows durable responses in lymph-node-dominant metastatic gallbladder cancer</title>
		<link>https://bioengineer.org/immunotherapy-plus-chemotherapy-shows-durable-responses-in-lymph-node-dominant-metastatic-gallbladder-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:16:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[conversion surgery]]></category>
		<category><![CDATA[gallbladder cancer]]></category>
		<category><![CDATA[Gemcitabine]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[lymph-node metastases]]></category>
		<category><![CDATA[nab-paclitaxel]]></category>
		<category><![CDATA[PD-1 blockade]]></category>
		<category><![CDATA[RECIST]]></category>
		<category><![CDATA[Retrospective study]]></category>
		<category><![CDATA[SEER database]]></category>
		<category><![CDATA[single-cell transcriptomics]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464776</guid>

					<description><![CDATA[A retrospective Chinese study reports that all 11 patients with lymph-node-dominant metastatic gallbladder cancer responded to PD-1 blockade plus gemcitabine and nab-paclitaxel, with six complete responses and a 100 percent one-year survival rate.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464776</post-id>	</item>
		<item>
		<title>Older Lung Cancer Patients Struggle to Keep Exercising After Leaving Hospital</title>
		<link>https://bioengineer.org/older-lung-cancer-patients-struggle-to-keep-exercising-after-leaving-hospital/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:11:59 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[content analysis]]></category>
		<category><![CDATA[discharge follow-up]]></category>
		<category><![CDATA[family support]]></category>
		<category><![CDATA[hospital-to-home transition]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[older patients]]></category>
		<category><![CDATA[patient interviews]]></category>
		<category><![CDATA[postoperative recovery]]></category>
		<category><![CDATA[qualitative study]]></category>
		<category><![CDATA[rehabilitation exercise]]></category>
		<category><![CDATA[social ecological model]]></category>
		<category><![CDATA[Zhejiang China]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464728</guid>

					<description><![CDATA[A qualitative study of thirteen older patients in China finds that symptom burden, family support, and gaps in post-discharge medical follow-up shape rehabilitation exercise after lung cancer surgery.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464728</post-id>	</item>
		<item>
		<title>Gut Microbes in Colorectal Cancer: Why Species Lists Are Not Enough</title>
		<link>https://bioengineer.org/gut-microbes-in-colorectal-cancer-why-species-lists-are-not-enough/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:07:04 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Beyond]]></category>
		<category><![CDATA[Candida albicans]]></category>
		<category><![CDATA[Colorectal cancer]]></category>
		<category><![CDATA[dysbiosis]]></category>
		<category><![CDATA[Fudan University]]></category>
		<category><![CDATA[Fusobacterium nucleatum]]></category>
		<category><![CDATA[Gut microbiome]]></category>
		<category><![CDATA[Microbial biomarkers]]></category>
		<category><![CDATA[microbial metabolites]]></category>
		<category><![CDATA[Microbiology China]]></category>
		<category><![CDATA[microbiome interventions]]></category>
		<category><![CDATA[strain-level variation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464679</guid>

					<description><![CDATA[A review from Fudan and Tongji University researchers links multi-kingdom microbial interactions and strain-level genetic variation to colorectal cancer mechanisms, biomarkers and experimental interventions.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464679</post-id>	</item>
		<item>
		<title>Nearly 6 in 10 Americans now know alcohol raises cancer risk, survey finds</title>
		<link>https://bioengineer.org/nearly-6-in-10-americans-now-know-alcohol-raises-cancer-risk-survey-finds/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:05:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Alcohol]]></category>
		<category><![CDATA[Annenberg Public Policy Center]]></category>
		<category><![CDATA[ASAPH survey]]></category>
		<category><![CDATA[Cancer risk]]></category>
		<category><![CDATA[dietary guidelines]]></category>
		<category><![CDATA[health communication]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[Public]]></category>
		<category><![CDATA[public health survey]]></category>
		<category><![CDATA[Risk Perception]]></category>
		<category><![CDATA[surgeon general advisory]]></category>
		<category><![CDATA[U.S. adults]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464651</guid>

					<description><![CDATA[A nationally representative Annenberg survey finds that 58 percent of U.S. adults know regular drinking increases cancer risk, a five-point rise since February 2026.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464651</post-id>	</item>
		<item>
		<title>NCCN launches free patient guide to help caregivers support loved ones with cancer</title>
		<link>https://bioengineer.org/nccn-launches-free-patient-guide-to-help-caregivers-support-loved-ones-with-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:05:38 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer care]]></category>
		<category><![CDATA[cancer support]]></category>
		<category><![CDATA[caregivers]]></category>
		<category><![CDATA[Caregiving for People with Cancer]]></category>
		<category><![CDATA[emotional support]]></category>
		<category><![CDATA[family-centered cancer care]]></category>
		<category><![CDATA[free resource]]></category>
		<category><![CDATA[medical management]]></category>
		<category><![CDATA[NCCN]]></category>
		<category><![CDATA[NCCN Foundation]]></category>
		<category><![CDATA[patient guidelines]]></category>
		<category><![CDATA[self-care]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464647</guid>

					<description><![CDATA[The National Comprehensive Cancer Network has released its first free patient guideline dedicated to supporting people who care for loved ones with cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464647</post-id>	</item>
		<item>
		<title>Gut-organ axis research mapped over 25 years reveals major gaps in translation</title>
		<link>https://bioengineer.org/gut-organ-axis-research-mapped-over-25-years-reveals-major-gaps-in-translation/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:05:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Bibliometric Review]]></category>
		<category><![CDATA[Fecal microbiota transplantation]]></category>
		<category><![CDATA[gut microbiota]]></category>
		<category><![CDATA[gut-organ axis]]></category>
		<category><![CDATA[host-microbiota communication]]></category>
		<category><![CDATA[MASTER]]></category>
		<category><![CDATA[microbiome therapeutics]]></category>
		<category><![CDATA[microbiota]]></category>
		<category><![CDATA[postbiotics]]></category>
		<category><![CDATA[probiotics]]></category>
		<category><![CDATA[Translational Research]]></category>
		<category><![CDATA[TransMed]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464635</guid>

					<description><![CDATA[A 25-year bibliometric review in TransMed finds gut-organ axis research unevenly developed, with several axes lacking interventional trials and current microbiota therapies constrained by small, heterogeneous studies.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464635</post-id>	</item>
		<item>
		<title>Long-Term Trial Data Show Triplet Therapy Extends Survival in Metastatic Prostate Cancer</title>
		<link>https://bioengineer.org/long-term-trial-data-show-triplet-therapy-extends-survival-in-metastatic-prostate-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 28 Oct 2026 00:01:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[Androgen deprivation therapy]]></category>
		<category><![CDATA[castration-sensitive prostate cancer]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[docetaxel]]></category>
		<category><![CDATA[ESMO Congress 2026]]></category>
		<category><![CDATA[metastatic cancer]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[PEACE-1 trial]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[treatment intensification]]></category>
		<category><![CDATA[triplet therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464615</guid>

					<description><![CDATA[Long-term PEACE-1 trial results show that adding abiraterone to ADT and docetaxel reduced the risk of death by 32 percent in men with metastatic prostate cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464615</post-id>	</item>
		<item>
		<title>Negative Coombs Test Does Not Exclude Immune Anemia</title>
		<link>https://bioengineer.org/negative-coombs-test-does-not-exclude-immune-anemia/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:57:37 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[autoimmune hemolytic anemia]]></category>
		<category><![CDATA[case report]]></category>
		<category><![CDATA[Coombs-negative]]></category>
		<category><![CDATA[diagnostic challenge]]></category>
		<category><![CDATA[Hematology]]></category>
		<category><![CDATA[hemolytic]]></category>
		<category><![CDATA[Immune checkpoint inhibitors]]></category>
		<category><![CDATA[immune-related adverse events]]></category>
		<category><![CDATA[metastatic lung cancer]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[pembrolizumab)]]></category>
		<category><![CDATA[rare]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464591</guid>

					<description><![CDATA[A case report in Oncoscience details a patient with metastatic lung cancer who developed severe Coombs-negative hemolytic anemia after pembrolizumab treatment, highlighting the limitations of standard serologic tests in diagnosing immune-related adverse events.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464591</post-id>	</item>
		<item>
		<title>Ultrasound-Boosted Implant Aims to Push Drugs Deeper Into the Brain</title>
		<link>https://bioengineer.org/ultrasound-boosted-implant-aims-to-push-drugs-deeper-into-the-brain/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:56:58 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Blood-brain barrier]]></category>
		<category><![CDATA[brain tumor]]></category>
		<category><![CDATA[convection-enhanced delivery]]></category>
		<category><![CDATA[Device journal]]></category>
		<category><![CDATA[Drug delivery]]></category>
		<category><![CDATA[Glioblastoma]]></category>
		<category><![CDATA[implantable device]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[mouse study]]></category>
		<category><![CDATA[Neurotechnology]]></category>
		<category><![CDATA[osmotic pump]]></category>
		<category><![CDATA[ultrasound]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464575</guid>

					<description><![CDATA[MIT researchers have built an implantable device that pairs a 24-transducer ultrasound array with a drug-delivery cannula to spread therapeutic molecules farther through brain tissue, a step they hope could help prevent the recurrence of glioblastoma.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464575</post-id>	</item>
		<item>
		<title>Alpha-Emitting Prostate Cancer Therapy 212Pb-ADVC001 Well Tolerated in First-in-Human Trial</title>
		<link>https://bioengineer.org/alpha-emitting-prostate-cancer-therapy-212pb-advc001-well-tolerated-in-first-in-human-trial/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:52:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[212Pb-ADVC001]]></category>
		<category><![CDATA[alpha emitter]]></category>
		<category><![CDATA[dose escalation]]></category>
		<category><![CDATA[lutetium-177]]></category>
		<category><![CDATA[metastatic castration-resistant prostate cancer]]></category>
		<category><![CDATA[nuclear medicine]]></category>
		<category><![CDATA[Phase 1 trial]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[PSA response]]></category>
		<category><![CDATA[PSMA]]></category>
		<category><![CDATA[radiopharmaceutical therapy]]></category>
		<category><![CDATA[TheraPb trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464531</guid>

					<description><![CDATA[In the first-in-human TheraPb phase 1 trial, the alpha-emitting radiopharmaceutical 212Pb-ADVC001 was well tolerated at doses of 60–200 MBq with no dose-limiting toxicities, and early results showed PSA declines of at least 50 percent in 80 percent of patients with metastatic prostate cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464531</post-id>	</item>
		<item>
		<title>King Power Group Hong Kong CEO Sunil Tuli Joins Asian Fund for Cancer Research Board</title>
		<link>https://bioengineer.org/king-power-group-hong-kong-ceo-sunil-tuli-joins-asian-fund-for-cancer-research-board/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:51:55 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[AFCR]]></category>
		<category><![CDATA[APTRA]]></category>
		<category><![CDATA[Asia-Pacific]]></category>
		<category><![CDATA[board appointment]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[fundraising]]></category>
		<category><![CDATA[Hong Kong]]></category>
		<category><![CDATA[King Power Group Hong Kong]]></category>
		<category><![CDATA[nonprofit]]></category>
		<category><![CDATA[philanthropy]]></category>
		<category><![CDATA[Sunil Tuli]]></category>
		<category><![CDATA[travel retail]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464503</guid>

					<description><![CDATA[The Asian Fund for Cancer Research has appointed King Power Group Hong Kong CEO and APTRA President Sunil Tuli to its Board of Directors, adding four decades of international business leadership and a record of personal fundraising for cancer research.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464503</post-id>	</item>
		<item>
		<title>First-in-Human Trial Uses Laser Light to Attack Inoperable Pancreatic Tumors</title>
		<link>https://bioengineer.org/first-in-human-trial-uses-laser-light-to-attack-inoperable-pancreatic-tumors/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:51:13 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[ImPact Biotech]]></category>
		<category><![CDATA[interventional radiology]]></category>
		<category><![CDATA[laser ablation]]></category>
		<category><![CDATA[locally advanced pancreatic ductal adenocarcinoma]]></category>
		<category><![CDATA[padeliporfin]]></category>
		<category><![CDATA[pancreatic cancer]]></category>
		<category><![CDATA[Phase 1 trial]]></category>
		<category><![CDATA[photodynamic therapy]]></category>
		<category><![CDATA[surgical margins]]></category>
		<category><![CDATA[UCI Health]]></category>
		<category><![CDATA[vascular-targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464486</guid>

					<description><![CDATA[A first-in-human phase 1 trial at UCI Health is using padeliporfin vascular-targeted photodynamic therapy to destroy pancreatic tumors encasing major arteries, with preliminary results showing clear surgical margins in three of four patients who underwent tumor removal.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464486</post-id>	</item>
		<item>
		<title>Fewer low-risk prostate cancers treated as active surveillance becomes the norm</title>
		<link>https://bioengineer.org/fewer-low-risk-prostate-cancers-treated-as-active-surveillance-becomes-the-norm/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:46:32 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[active surveillance]]></category>
		<category><![CDATA[Cancer Epidemiology]]></category>
		<category><![CDATA[CANCER journal]]></category>
		<category><![CDATA[low-risk cancer]]></category>
		<category><![CDATA[Overdiagnosis]]></category>
		<category><![CDATA[overtreatment]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[PSA screening]]></category>
		<category><![CDATA[Radiation Therapy]]></category>
		<category><![CDATA[SEER]]></category>
		<category><![CDATA[University of Michigan]]></category>
		<category><![CDATA[Veterans Affairs]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464438</guid>

					<description><![CDATA[An analysis of United States registry and health system data shows low-risk prostate cancer is being diagnosed less often and, when found, is increasingly managed with active surveillance rather than immediate treatment.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464438</post-id>	</item>
		<item>
		<title>Multimodal AI maps the path to personalized cancer immunotherapy</title>
		<link>https://bioengineer.org/multimodal-ai-maps-the-path-to-personalized-cancer-immunotherapy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:43:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[AI virtual cells]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[Clinical decision support]]></category>
		<category><![CDATA[digital pathology]]></category>
		<category><![CDATA[foundation models]]></category>
		<category><![CDATA[immune-related adverse events]]></category>
		<category><![CDATA[Multimodal AI]]></category>
		<category><![CDATA[pseudoprogression]]></category>
		<category><![CDATA[radiomics]]></category>
		<category><![CDATA[Science Bulletin]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464426</guid>

					<description><![CDATA[A Science Bulletin review outlines how multimodal artificial intelligence integrating molecular, cellular, and clinical data could refine immunotherapy decisions while warning that routine clinical use remains distant.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464426</post-id>	</item>
		<item>
		<title>Machine learning models flag higher cancer risk from routine health data</title>
		<link>https://bioengineer.org/machine-learning-models-flag-higher-cancer-risk-from-routine-health-data/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:38:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[AUROC]]></category>
		<category><![CDATA[blood tests]]></category>
		<category><![CDATA[cancer risk prediction]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[ESMO Congress 2026]]></category>
		<category><![CDATA[Large Language Models]]></category>
		<category><![CDATA[Machine Learning]]></category>
		<category><![CDATA[PRE-Screen]]></category>
		<category><![CDATA[prospective validation]]></category>
		<category><![CDATA[routine health data]]></category>
		<category><![CDATA[screening]]></category>
		<category><![CDATA[UK Biobank]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464378</guid>

					<description><![CDATA[Machine learning models using routine health data showed potential to identify people at higher risk of several common cancers, with performance varying across cancer types and prospective studies still needed.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464378</post-id>	</item>
		<item>
		<title>Omega-3 EPA tied to longer survival after liver surgery for bowel cancer spread</title>
		<link>https://bioengineer.org/omega-3-epa-tied-to-longer-survival-after-liver-surgery-for-bowel-cancer-spread/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:37:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[cachexia]]></category>
		<category><![CDATA[Colorectal cancer]]></category>
		<category><![CDATA[EMT2 trial]]></category>
		<category><![CDATA[EPA]]></category>
		<category><![CDATA[ESMO Congress 2026]]></category>
		<category><![CDATA[icosapent ethyl]]></category>
		<category><![CDATA[Liver Metastases]]></category>
		<category><![CDATA[liver resection]]></category>
		<category><![CDATA[omega-3]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[phase 3 trial]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464358</guid>

					<description><![CDATA[In the phase 3 EMT2 trial, high-dose EPA was associated with longer overall survival but not improved progression-free survival after surgery for colorectal cancer liver metastases.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464358</post-id>	</item>
		<item>
		<title>Perioperative apalutamide cuts metastasis and death risk in high-risk prostate cancer substudy</title>
		<link>https://bioengineer.org/perioperative-apalutamide-cuts-metastasis-and-death-risk-in-high-risk-prostate-cancer-substudy/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:28:58 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Androgen deprivation therapy]]></category>
		<category><![CDATA[androgen-receptor pathway inhibitor]]></category>
		<category><![CDATA[apalutamide]]></category>
		<category><![CDATA[Dana-Farber Cancer Institute]]></category>
		<category><![CDATA[ESMO Congress 2026]]></category>
		<category><![CDATA[European Urology]]></category>
		<category><![CDATA[event-free survival]]></category>
		<category><![CDATA[metastasis risk]]></category>
		<category><![CDATA[perioperative therapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[PROTEUS trial]]></category>
		<category><![CDATA[radical prostatectomy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464274</guid>

					<description><![CDATA[A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around radical prostatectomy improved event-free survival by 62 percent and reduced the risk of metastasis or death by 51 percent in men with high-risk localized or locally advanced prostate cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464274</post-id>	</item>
		<item>
		<title>First NCI Award at UT Knoxville Funds Family-Based Pain Care for Appalachian Breast Cancer Survivors</title>
		<link>https://bioengineer.org/first-nci-award-at-ut-knoxville-funds-family-based-pain-care-for-appalachian-breast-cancer-survivors/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:25:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[adjuvant endocrine therapy]]></category>
		<category><![CDATA[Appalachia]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[cancer survivorship]]></category>
		<category><![CDATA[College of Nursing]]></category>
		<category><![CDATA[Family Caregivers]]></category>
		<category><![CDATA[National Cancer Institute]]></category>
		<category><![CDATA[Pain Management]]></category>
		<category><![CDATA[pilot trial]]></category>
		<category><![CDATA[Quality of Life]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[University of Tennessee Knoxville]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464270</guid>

					<description><![CDATA[The University of Tennessee Knoxville College of Nursing has received its first funded National Cancer Institute award, a two-year project testing a telehealth, family-based pain intervention for Appalachian breast cancer survivors taking adjuvant endocrine therapies.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464270</post-id>	</item>
		<item>
		<title>Research report: Addressing the side effects of endocrine therapy: a new care pathway combining digital support and human expertise</title>
		<link>https://bioengineer.org/research-report-addressing-the-side-effects-of-endocrine-therapy-a-new-care-pathway-combining-digital-support-and-human-expertise/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:25:22 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[Digital Health]]></category>
		<category><![CDATA[endocrine therapy]]></category>
		<category><![CDATA[ESMO 2026]]></category>
		<category><![CDATA[Gustave Roussy]]></category>
		<category><![CDATA[HOPE trial]]></category>
		<category><![CDATA[hormone receptor-positive]]></category>
		<category><![CDATA[mobile application]]></category>
		<category><![CDATA[nurse support]]></category>
		<category><![CDATA[supportive care]]></category>
		<category><![CDATA[symptom management]]></category>
		<category><![CDATA[Treatment adherence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464258</guid>

					<description><![CDATA[A randomised phase III trial presented at ESMO 2026 shows that a hybrid care pathway combining a mobile application with personalised nurse support significantly improved breast cancer patients' confidence in managing endocrine therapy side effects, with symptom burden reductions that fell just short of statistical significance.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464258</post-id>	</item>
		<item>
		<title>Tumour location shapes survival in rare leiomyosarcoma, study of 11,700 patients finds</title>
		<link>https://bioengineer.org/tumour-location-shapes-survival-in-rare-leiomyosarcoma-study-of-11700-patients-finds/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 23:25:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer survival]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Health disparities]]></category>
		<category><![CDATA[Journal of the National Cancer Institute]]></category>
		<category><![CDATA[leiomyosarcoma]]></category>
		<category><![CDATA[personalised medicine]]></category>
		<category><![CDATA[rare cancers]]></category>
		<category><![CDATA[soft tissue sarcoma]]></category>
		<category><![CDATA[tumour biology]]></category>
		<category><![CDATA[tumour location]]></category>
		<category><![CDATA[University of Edinburgh]]></category>
		<category><![CDATA[uterine cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=464250</guid>

					<description><![CDATA[A University of Edinburgh analysis of 11,700 leiomyosarcoma cases shows that survival and tumour biology differ markedly depending on where the cancer arises in the body.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">464250</post-id>	</item>
	</channel>
</rss>
